Webinar | July 27, 2021

Partner Perspectives To De-Risk Commercialization Of Combination Products

Developing an effective drug-device combination product for self-administered biologics is a complex process. It requires critical decisions during delivery system selection. Making the right choices at an early stage can reduce risks throughout your drug development journey. Ultimately, a well-executed strategy will help support integration with manufacturing operations and successful drug delivery.

During this webinar, BD and PCI share insights on topics including:

  • Design space evolution and potential trade-offs when selecting device components for combination products
  • Approaches to de-risk your drug delivery system
  • Factors to consider when selecting a CDMO for secondary device assembly with biologics
  • Insights into how your delivery system and key partners can support successful commercialization of your combination product
VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: